Lexicon Pharmaceuticals’ (LXRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note issued to investors on Monday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $2.50.

Lexicon Pharmaceuticals Stock Up 3.4 %

Shares of NASDAQ LXRX opened at $0.34 on Monday. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.83. The business’s 50 day moving average is $0.74 and its two-hundred day moving average is $1.16. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. The firm has a market cap of $82.74 million, a price-to-earnings ratio of -0.45 and a beta of 1.04.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Bayesian Capital Management LP acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth $31,000. RPO LLC acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth $33,000. Renaissance Technologies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth $38,000. Arizona State Retirement System grew its stake in shares of Lexicon Pharmaceuticals by 34.4% during the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 16,136 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its stake in shares of Lexicon Pharmaceuticals by 60.3% during the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 24,615 shares in the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.